Literature DB >> 22354960

c-Jun and Ets2 proteins regulate expression of spleen tyrosine kinase in T cells.

Debjani Ghosh1, George C Tsokos, Vasileios C Kyttaris.   

Abstract

Effector T cells and T cells from patients with systemic lupus erythematosus (SLE) express increased levels of the spleen tyrosine kinase (Syk). Syk binds to the T cell receptor (TCR)-CD3 complex and transduces the TCR-mediated signal in the cell more efficiently than the canonical CD3ζ chain. The reasons for the increased expression of Syk are unclear. In the present study, we found that Syk is regulated by the transcription factor c-Jun in cooperation with Ets2. c-Jun and Ets2 bound to the SYK promoter in close proximity and increased the promoter activity in a specific manner. Disruption of c-Jun and Ets2 expression by siRNA resulted in decreased expression of Syk. Overexpression of c-Jun but not Ets2 resulted in increase in Syk protein. c-Jun and Ets2 co-immunoprecipitated and had an additive effect on Syk expression. c-Jun-driven SYK promoter activation showed a similar pattern in B cells; however, as expected, basal promoter activity was much higher in B cells as compared with T cells. Overexpression of c-Jun led to increase in intracytoplasmic calcium flux following TCR stimulation. Moreover, we found that SLE T cells had increased levels of c-Jun at baseline and phosphorylated c-Jun upon activation. Finally, disruption of c-Jun and Ets2 in SLE T cells resulted in a decrease in calcium flux upon TCR stimulation. In conclusion, c-Jun in cooperation with Ets2 increases the expression of Syk and contributes to Syk-mediated heightened calcium responses in SLE T cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22354960      PMCID: PMC3320931          DOI: 10.1074/jbc.M111.333997

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  CREMα suppresses spleen tyrosine kinase expression in normal but not systemic lupus erythematosus T cells.

Authors:  Debjani Ghosh; Katalin Kis-Toth; Yuang-Taung Juang; George C Tsokos
Journal:  Arthritis Rheum       Date:  2012-03

2.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

Authors:  C Bombardier; D D Gladman; M B Urowitz; D Caron; C H Chang
Journal:  Arthritis Rheum       Date:  1992-06

3.  Transactivation by hepatitis B virus X protein is promiscuous and dependent on mitogen-activated cellular serine/threonine kinases.

Authors:  J C Cross; P Wen; W J Rutter
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

4.  JNK is required for effector T-cell function but not for T-cell activation.

Authors:  C Dong; D D Yang; C Tournier; A J Whitmarsh; J Xu; R J Davis; R A Flavell
Journal:  Nature       Date:  2000-05-04       Impact factor: 49.962

5.  Transcriptional regulation of the mouse steroidogenic acute regulatory protein gene by the cAMP response-element binding protein and steroidogenic factor 1.

Authors:  P R Manna; D W Eubank; E Lalli; P Sassone-Corsi; D M Stocco
Journal:  J Mol Endocrinol       Date:  2003-06       Impact factor: 5.098

6.  Reconstitution of deficient T cell receptor zeta chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with systemic lupus erythematosus.

Authors:  Madhusoodana P Nambiar; Carolyn U Fisher; Vishal G Warke; Sandeep Krishnan; Jeanne P Mitchell; Nancy Delaney; George C Tsokos
Journal:  Arthritis Rheum       Date:  2003-07

7.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei.

Authors:  J D Dignam; R M Lebovitz; R G Roeder
Journal:  Nucleic Acids Res       Date:  1983-03-11       Impact factor: 16.971

8.  Assessment of the role of activator protein-1 on transcription of the mouse steroidogenic acute regulatory protein gene.

Authors:  Pulak R Manna; Darrell W Eubank; Douglas M Stocco
Journal:  Mol Endocrinol       Date:  2003-12-12

9.  In vivo protein-DNA interactions at the c-jun promoter: preformed complexes mediate the UV response.

Authors:  D Rozek; G P Pfeifer
Journal:  Mol Cell Biol       Date:  1993-09       Impact factor: 4.272

Review 10.  Targeting JNK for therapeutic benefit: from junk to gold?

Authors:  Anthony M Manning; Roger J Davis
Journal:  Nat Rev Drug Discov       Date:  2003-07       Impact factor: 84.694

View more
  6 in total

1.  ETS2 promotes epithelial-to-mesenchymal transition in renal fibrosis by targeting JUNB transcription.

Authors:  Fang Yao; Xiaojing Wang; Zhong-Kai Cui; Haibing Lan; Xiaolan Ai; Qiancheng Song; Zhenguo Chen; Jun Yang; Bingyi Wu; Xiaochun Bai
Journal:  Lab Invest       Date:  2019-10-22       Impact factor: 5.662

2.  BLK pathway-associated rs13277113 GA genotype is more frequent in SLE patients and associated with low gene expression and increased flares.

Authors:  Omer Nuri Pamuk; Hakan Gurkan; Gulsum Emel Pamuk; Hilmi Tozkır; Julide Duymaz; Metin Yazar
Journal:  Clin Rheumatol       Date:  2016-11-18       Impact factor: 2.980

3.  Spleen tyrosine kinase (Syk) regulates systemic lupus erythematosus (SLE) T cell signaling.

Authors:  Alexandros P Grammatikos; Debjani Ghosh; Amy Devlin; Vasileios C Kyttaris; George C Tsokos
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

Review 4.  The pathology of T cells in systemic lupus erythematosus.

Authors:  Anselm Mak; Nien Yee Kow
Journal:  J Immunol Res       Date:  2014-04-23       Impact factor: 4.818

Review 5.  Disturbed T Cell Signaling and Altered Th17 and Regulatory T Cell Subsets in the Pathogenesis of Systemic Lupus Erythematosus.

Authors:  Nils Rother; Johan van der Vlag
Journal:  Front Immunol       Date:  2015-11-30       Impact factor: 7.561

6.  Ets-2 deletion in myeloid cells attenuates IL-1α-mediated inflammatory disease caused by a Ptpn6 point mutation.

Authors:  Sarang Tartey; Prajwal Gurung; Rajendra Karki; Amanda Burton; Paul Hertzog; Thirumala-Devi Kanneganti
Journal:  Cell Mol Immunol       Date:  2020-03-19       Impact factor: 22.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.